Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line

Upstream Bio (NASDAQ:UPB) was downgraded by equities research analysts at Evercore from an “outperform” rating to an “in-line” rating in a research report issued to clients and investors on Friday. They currently have a $15.00 target price on the stock. Evercore’s price target points to a potential upside of 53.22% from the company’s current price.

Several other equities analysts have also commented on UPB. Lifesci Capital initiated coverage on Upstream Bio in a research note on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Finally, Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Upstream Bio Stock Performance

UPB stock opened at $9.79 on Friday. Upstream Bio has a one year low of $5.14 and a one year high of $33.68. The firm has a market cap of $529.05 million, a PE ratio of -5.21 and a beta of 2.96. The firm’s 50 day moving average price is $16.38 and its 200-day moving average price is $21.42.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The business had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.52 million. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%. Equities research analysts predict that Upstream Bio will post -4.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Upstream Bio

Institutional investors have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC lifted its stake in Upstream Bio by 6.3% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock worth $26,786,000 after acquiring an additional 144,216 shares in the last quarter. Integral Health Asset Management LLC acquired a new position in Upstream Bio in the 3rd quarter valued at about $10,816,000. Geode Capital Management LLC grew its position in Upstream Bio by 57.5% in the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock valued at $7,101,000 after acquiring an additional 235,958 shares in the last quarter. Norges Bank purchased a new stake in Upstream Bio during the second quarter worth about $10,650,000. Finally, Virtus Investment Advisers LLC purchased a new stake in Upstream Bio during the second quarter worth about $89,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.